IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
相关临床试验
4
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
50.0%
已完成
1
25.0%
招募中
1
25.0%
暂无批准数据
- IO Biotech, a clinical-stage biopharmaceutical company developing T-win cancer vaccines, announced it is exploring strategic alternatives including potential merger, sale, or liquidation to maximize stockholder value. - The company has retained Raymond James & Associates as exclusive financial advisor to assist in the strategic review process announced in January 2026. - IO Biotech is implementing significant cost-containment measures including workforce reductions while exploring alternatives for its novel immune-modulatory cancer vaccine platform. - The T-win platform represents a unique approach to cancer vaccines designed to activate T cells against both tumor cells and immune-suppressive cells in the tumor microenvironment.
- IO Biotech published five-year follow-up data from its Phase 1/2 MM1636 trial showing IO102-IO103 combined with nivolumab achieved a median progression-free survival of 25.5 months in metastatic melanoma patients. - The study demonstrated a median duration of response exceeding 53 months and median overall survival of 60 months, with vaccine-specific immune biomarkers suggesting distinct immune modulation not seen with anti-PD-1 monotherapy. - These results supported FDA Breakthrough Therapy Designation and provided the foundation for IO Biotech's Phase 3 trial IOB-013/KN-D18, which completed enrollment with 407 patients in December 2023.
- IO Biotech presented preclinical data for two new T-win vaccine candidates, IO112 targeting arginase 1 and IO170 targeting TGF-β, at the Society for Immunotherapy of Cancer's 40th Annual Meeting. - IO112 demonstrated anti-tumor activity by modulating immunosuppressive myeloid cells and tumor-associated macrophages, shifting the tumor microenvironment from immunosuppressive to pro-inflammatory. - IO170 showed significant tumor growth inhibition and reduction of lung metastasis through TGF-β-specific T cell activation in preclinical cancer models. - The company plans to file an Investigational New Drug Application for IO112 in 2026, marking the next candidate expected to enter clinical development.
- IO Biotech is laying off half of its workforce this week following the FDA's advice against submitting an application for its cancer drug candidate based on existing data. - The company plans to proceed with a US Phase 3 trial despite the regulatory setback and current funding challenges. - The biotech faces significant financial constraints requiring substantial cost reductions as part of a new strategic plan to secure its future operations.
- Over 25 pharmaceutical companies are actively developing 30+ TGF-β inhibitors to address significant unmet needs in oncology and fibrosis where existing therapies show limited effectiveness. - Key pipeline advances include Keros Therapeutics initiating Phase III trials for elritercept in myelodysplastic syndromes and EpicentRx receiving FDA Fast Track designation for AdAPT-001 in soft tissue sarcoma. - Recent clinical milestones demonstrate promising efficacy across multiple indications, with companies like Isarna Therapeutics reporting positive Phase II results for retinal fibrosis treatment ISTH0036.
- IO Biotech's Phase 3 clinical trial has failed to deliver on its primary objectives, marking a significant setback for the company's development program. - The trial failure represents a major disappointment for investors and stakeholders who had anticipated positive results from the late-stage study. - This development highlights the inherent risks in pharmaceutical development, where even promising therapies can fail in advanced clinical testing phases.
- IO Biotech's therapeutic cancer vaccine Cylembio combined with pembrolizumab achieved a median progression-free survival of 19.4 months versus 11.0 months with pembrolizumab alone in advanced melanoma patients. - The combination showed particularly pronounced benefits in PD-L1-negative patients, with median PFS of 16.6 months compared to 3.0 months for pembrolizumab monotherapy. - Despite narrowly missing statistical significance (p=0.056), the company plans to meet with FDA this fall to discuss potential regulatory pathways for approval. - The treatment was well-tolerated with no new safety signals, with injection site reactions being the most common adverse event in 56% of patients.
- IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056. - The combination therapy demonstrated a median progression-free survival of 19.4 months versus 11.0 months for Keytruda monotherapy, with particularly strong results in PD-L1-negative patients showing 16.6 months versus 3.0 months. - Despite the primary endpoint miss, IO Biotech plans to meet with the FDA in Q3 to discuss potential approval based on subgroup analyses, including a 46% risk reduction in patients testing negative for immunotherapy response proteins. - The company's stock fell over 20% following the announcement, reflecting investor skepticism about regulatory approval prospects despite the narrow statistical miss.
- IO Biotech's Phase 3 trial of cancer vaccine Cylembio combined with pembrolizumab showed over 8 months median progression-free survival benefit in advanced melanoma patients but narrowly missed statistical significance for the primary endpoint. - The company's stock plunged 34.25% to $1.19 following the announcement, with CEO Mai-Britt Zocca stating the trial missed the primary endpoint "by a hair." - Despite mixed results, H.C. Wainwright analyst Emily Bodnar maintains a Buy rating with $14.00 price target, citing the significant survival benefit and comparable safety profile. - IO Biotech plans to engage with the FDA this fall to discuss the data package and potential regulatory pathways forward.
- IO Biotech announced that its cancer vaccine Cylembio combined with KEYTRUDA showed improvement in progression-free survival over KEYTRUDA alone but narrowly missed statistical significance for the primary endpoint in advanced melanoma. - The disappointing Phase 3 trial results caused IO Biotech's stock to plunge 34.25% to $1.19, with trading volume surging to 70.37 million shares compared to the average of 0.32 million shares. - Despite the setback, analysts maintain an average target price of $8.20, indicating a potential 324% upside, while the company continues development of its T-Win Technology platform for off-the-shelf therapeutic vaccines. - IO Biotech has sufficient cash reserves of $37.1 million to fund operations into Q2 2026, though the company burns approximately $22.6 million per quarter on research and development activities.
